What is it about?
Integrase inhibitors like dolutegravir are highly effective for HIV treatment, but rare drug resistance mutations (DRMs) are emerging. This report highlights three Indian cases of INSTI resistance likely acquired through transmission. These mutations impact treatment decisions, emphasizing the need for routine resistance testing and personalized care to prevent the spread of resistant HIV.
Featured Image
Photo by National Institute of Allergy and Infectious Diseases on Unsplash
Why is it important?
This is important because drug resistance to integrase inhibitors, though rare, can limit treatment options and compromise HIV management. Identifying and addressing such resistance early through routine testing helps ensure effective treatment, prevents further spread of resistant strains, and safeguards the long-term success of HIV therapies.
Perspectives
Integrase inhibitors (INSTIs) have revolutionized HIV treatment, becoming its cornerstone due to their effectiveness and tolerability. However, the emergence of drug resistance mutations (DRMs), even in patients who have never used these drugs, is a concerning trend. These cases from India serve as a wake-up call, highlighting the need for routine resistance testing to detect such mutations early. As HIV care evolves, it’s clear that personalized treatment and proactive surveillance are essential to maintain the effectiveness of INSTIs and to stay ahead in the fight against drug-resistant HIV.
Dr. Nishant Raman
Read the Original
This page is a summary of: Emergence of Integrase Strand Transfer Inhibitors Resistance Mutations in Multidrug-Resistant Human Immunodeficiency Virus Strains Detected in Integrase Strand Transfer Inhibitors Naïve Indian Persons Living with Human Immunodeficiency Virus: A Report ..., Journal of Clinical Infectious Disease Society, October 2024, Wolters Kluwer Health,
DOI: 10.4103/cids.cids_43_24.
You can read the full text:
Contributors
The following have contributed to this page
